Home > Healthcare > Analytical Instruments > Molecular Analysis > Nucleic Acid Amplification Testing Market
Nucleic Acid Amplification Testing Market Size
- Report ID: GMI8506
- Published Date: Mar 2024
- Report Format: PDF
Nucleic Acid Amplification Testing Market Size
Nucleic Acid Amplification Testing Market size was valued at around USD 7.3 billion in 2023 and is estimated to reach over USD 18.8 billion by 2032. Nucleic acid amplification testing (NAAT) is a molecular technique used to amplify and detect specific sequences of nucleic acids, such as DNA or RNA, within a sample. NAAT is employed in various fields including medical diagnostics, microbiology, and genetic research.
Infectious diseases continue to pose a significant threat to global public health. The increasing prevalence of diseases such as HIV/AIDS, tuberculosis, hepatitis, and sexually transmitted infections necessitates accurate and rapid diagnostic methods. For instance, according to World Health Organization (WHO), in 2022, tuberculosis caused 1.3 million deaths, including 167,000 co-infected with HIV, making it the second leading infectious cause of death worldwide, surpassing HIV/AIDS.
There were 10.6 million new TB cases, affecting 5.8 million men, 3.5 million women, and 1.3 million children, highlighting its global prevalence across all demographics. Therefore, NAAT offers high sensitivity and specificity in detecting various pathogens, making it a crucial tool in the diagnosis and management of infectious diseases.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Nucleic Acid Amplification Testing Market Size in 2023: | USD 7.3 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 11.3% |
| 2032 Value Projection: | USD 18.8 Billion |
| Historical Data for: | 2018 - 2023 |
| No. of Pages: | 206 |
| Tables, Charts & Figures: | 340 |
| Segments covered: | Product Type, Technology, Application, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Point-of-care testing (POCT) which is estimated to reach USD 78.3 billion by 2023, with NAAT technologies allows for rapid, accurate infectious disease diagnostics even at the remote locations. With quick results and decentralized testing, POCT meets the demand for timely diagnosis, improving patient care and stimulating NAAT adoption across healthcare settings.
Frequently Asked Questions (FAQ) :
Nucleic Acid Amplification Testing Market Scope
